Vaginal gel holds potential as a female-controlled method of HIV prevention
March 16, 2009
A clinical trial involving more than 3,000 women in seven sites (six in Africa; one in the United States) has demonstrated for the first time that a vaginal microbicide gel may prevent male-to-female sexual transmission of HIV infection. The study investigators, including Drs. Benoit Masse and Barbra Richardson, statisticians in the Fred Hutchinson Cancer Research Center's Vaccine and Infectious Disease Institute, presented the findings at the recent Conference on Retroviruses and Opportunistic Infections in Montreal.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.